anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a single-center prospective study to evaluate the predictive value of circulating tumor cells (CTC) in patients with metastatic colorectal cancer who are planned to have curative resection of liver metastasis. Blood will be taken from patients within 7 days before liver resection. CTC enumeration is done by a highly-sensitive microfluidic platform for which CTC can be subsequently enumerated with or without sequencing performed. Patients are then followed up regularly with contrast CT scan for recurrence. The primary study endpoint is to define the cutoff value of CTC count in patients with early relapse \< 6months after liver resection. Seventy-seven patients will be recruited in 24 months.
OBJECTIVES: The present study investigated the relationship between bronchopulmonary dysplasia (BPD) and intra-amniotic infection with Ureaplasma species.
METHODS: This was a single-center, retrospective cohort study. Patients with singleton pregnancies who underwent inpatient management at our department for preterm premature rupture of membranes (PPROM), preterm labor, cervical insufficiency, and asymptomatic cervical shortening at 22-33 gestational weeks were included. Amniocentesis was indicated for patients with PPROM or an elevated maternal C-reactive protein level (≥0.58 mg/dL). Patients with an amniotic fluid IL-6 concentration ≥3.0 ng/mL were diagnosed with intra-amniotic inflammation, while those with positive aerobic, anaerobic, M. hominis, and Ureaplasma spp. cultures were diagnosed with microbial invasion of the amniotic cavity (MIAC). Patients who tested positive for both intra-amniotic inflammation and MIAC were considered to have intra-amniotic infection. An umbilical vein blood IL-6 concentration >11.0 pg/mL indicated fetal inflammatory response syndrome (FIRS). The maternal inflammatory response (MIR) and fetal inflammatory response (FIR) were staged using the Amsterdam Placental Workshop Group Consensus Statement.
RESULTS: Intra-amniotic infection with Ureaplasma spp. was diagnosed in 37 patients, intra-amniotic infection without Ureaplasma spp. in 28, intra-amniotic inflammation without MIAC in 58, and preterm birth without MIR/FIR and FIRS in 86 as controls. Following an adjustment for gestational age at birth, the risk of BPD was increased in patients with intra-amniotic infection with Ureaplasma spp. (adjusted odds ratio: 10.5; 95% confidence interval: 1.55-71.2), but not in those with intra-amniotic infection without Ureaplasma spp. or intra-amniotic inflammation without MIAC.
CONCLUSION: BPD was only associated with intra-amniotic infection with Ureaplasma species.
Preoperative chemoradiotherapy has been considered for years the standard treatment to patients with locally advanced rectal cancer. However, this multi-modality treatment has been questioned since more evidences suggested that radiotherapy may not be a necessary component of this treatment, and by omitting radiotherapy it have the advantage of reducing acute and late treatment-related toxicities. Given the high anti-tumor of systemic chemotherapy alone, any patients with CRM involvement could be theoretically deemed candidate for an approach in which radiotherapy is delivered preoperatively if a substantial tumor downsizing is not achieved after upfront systemic chemotherapy or postoperatively if the pathologic CRM is involved. This single phase Ⅱ trial was aimed to evaluate the efficacy of FOLFOXIRI in treating patients with MRI-defined CRM-positive rectal cancer. All patients will receive the regimen every 2 weeks for 3 cycles. MRI of the pelvic will be performed after 3 cycles of chemotherapy to assess clinical response. If the tumor responds after 3 cycles of treatment, the patient will continue for another 3 cycles of treatment before surgery under the decision of MDT. On the contrary, if the tumor shows no response, radiotherapy will be given before operation. After surgery and pathologic CRM is not involved, 6 cycles of mFOLFOX6 will be given as adjuvant chemotherapy, otherwise postoperative radiotherapy will be given if the pathologic CRM is involved.
PURPOSE: A pharmaceutical and food composition containing a polar solvent extract of Curcuma aromatica Salisb. containing curcumin, or a pharmaceutically acceptable carrier salt is provided which can be effectively used in the prevention and treatment of dementia. CONSTITUTION: Curcuma aromatica Salisb. is extracted in a polar solvent such as water, methanol, ethanol, acetone, chloroform, methylene chloride or a mixture thereof at 5 to 80deg.C for 30 to 55deg.C. Thus prepared Curcuma aromatica Salisb. extract contains 0.01 to 3% by weight of curcumin and is administered parenterally, transdermally at a daily dose of 1 to 1,000mg/kg of body weight.
PURPOSE:To obtain an endothelin inhibitor by using a compound having excellent endothelin antagonistic action and action to suppress the increase of intracellular calcium concentration as an active component. CONSTITUTION:A compound of formula I (R<1> is group of formula II, formula III, etc. ; R<2> and R<3> together form a single bond or R<2> is H and R<3> is group of formula IV) is used as an active component. The compound of formula I can be produced by culturing a microorganism belonging to the genus Streptomyces (e.g. Streptomyces sp. RE-1241 strain) in a medium and separating and purifying the compound produced and accumulated in the culture product. It can be formed in the form of oral or parenteral drug and the daily administration dose is 0.01-2mg/kg for adult. It is useful for the treatment of hypertension, asthma, cerebral apoplexy, acute renal insufficiency, myocardial infarction, stenocardia, cerebrovascular spasm, etc.
The study consists of two groups of children recruited in different centers in Korea. One group will receive the HRV vaccine and one group will receive the placebo. The vaccine or placebo will be administered starting at 2 months of age according to a two dose schedule (0, 2 months). The study will consist of three visits. At the first visit, one blood sample will be taken before vaccination and the first dose will be administered. At the second visit (2 months after first dose), the second vaccine will be administered. At the third visit (2 months after second dose), a blood sample will be taken. A 15-day (Day 0 - 14) follow-up period will be observed for general symptoms solicited in the study (fever, fussiness/irritability, diarrhea, vomiting, loss of appetite and cough/runny nose). A 43-day (Day 0 - 42) follow-up will be observed for other unsolicited symptoms. Serious adverse events will be followed-up throughout the study. A stool sample should be collected from the child at any point during the study if he/she develops any GE.
Glycosphingolipids (GSLs) bearing .alpha.-glucose (.alpha.-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with .alpha.-glucose (.alpha.-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with .alpha.-galactose (.alpha.-Gal) are disclosed. GSLs bearing .alpha.-glucose (.alpha.-Glc) and derivatives of .alpha.-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with a-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with .alpha.-Glc and derivatives thereof are provided. For example, the present disclosure includes an immune adjuvant compound having Formula (I) as well as its use, for example, for augmenting immunogenicity of an antigen in a subject. (see formula I)
SRT aims at consolidating sleep by limiting sleep to a specified time and restricting the amount of time spent in bed. Sleep time is individualized based on the persons' sleep needs, and the sleep-wake schedule is planned to fit the persons' lifestyle. The sleep-wake schedule is changed to accommodate improvements in the persons' sleep, over time.. A trained therapist will deliver the session in which the following topics will be covered: education about sleep, factors that influence sleep, behaviors that promote or interfere with sleep, and SRT. The session will be offered in a small group (4-6) format, based on availability of participants and to avoid any delay in treatment receipt.
FIELD: biotechnology, genetic engineering, molecular biology. SUBSTANCE: invention proposes the isolated DNA encoding protein gp 350. Protein gp 350 is used in pharmaceutical composition for treatment of EBV-mediated disease or state. Isolated DNA is a component of vector that is inserted in host-cell where expression of protein gp 350 occurs. DNA in vector composition excludes production of protein gp 220 and produces protein gp 350 only. EFFECT: improved method of protein preparing, valuable medicinal properties. 8 cl, 5 dwg, 3 tbl, 4 ex
The present invention relates to the gene PLOD2 which codes for telopeptide lysyl hydroxylase (TLH). This enzyme converts telopeptidyl Lys into telopeptidyl Hyl, that can subsequently be converted into hydroxyallysine cross-links. Collagen with hydroxyallysine cross-links shows a higher resistance to degradation by proteinases than collagen with cross-links derived from allysine. In one aspect, the invention provides methods and compositions to prepare collagenous materials with varying biodegradation rates by varying the ratio of hydroxyallysine cross-links over allysine cross-links. In another aspect, the invention provides methods and compositions to lower the ratio of hydroxyallysine cross-links over allysine cross-links in fibrotic processes, in order to obtain a collagenous network that is more easy to degrade. Furthermore, the invention provides methods to diagnose and/or monitor fibrotic processes by measuring mRNA levels of PLOD2, by measuring protein levels of the translated mRNA, and/or by measuring enzymatic activity levels of TLH. The invention also provides the description of a high through-put system facilitating the screening of antagonists of telopeptide lysyl hydroxylase.
Coordination between the stabilizer muscles of the trunk and respiratory functions may be lacking in people with chronic low back pain. However, a specially designed study investigating the relationship between respiratory functions and balance parameters in individuals with chronic low back pain is lacking. The goal of this observational study is to learn about respiratory muscle strength, respiratory functions, and balance in patients with chronic low back pain. Twenty-four individuals with low back pain for at least 6 months are going to include in the study. Pain assessment is going to assess with a Visual Analogue Scale. Respiratory muscle strength is going to measure by maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP). Pulmonary function assessment (PFT) is going to assess using a spirometer. Balance assessment is going to evaluate with Star Balance Test and Berg Balance Scale. Flexibility is going to evaluate with the Functional Reach Test.
PCT No. PCT/US96/10439 Sec. 371 Date Jun. 16, 1997 Sec. 102(e) Date Jun. 16, 1997 PCT Filed Jun. 7, 1996 PCT Pub. No. WO96/41616 PCT Pub. Date Dec. 27, 1996A formulation and methods for inducing sustained regional local anesthesia in a patient comprising a substrate comprising a local anesthetic and an effective amount of a biocompatible, biodegradable, controlled release material prolonging the release of the local anesthetic from the substrate to obtain a reversible local anesthesia when implanted or injected in a patient, and a pharmaceutically acceptable, i.e., non-toxic, non-glucocorticoid augmenting agent effective to prolong the duration of the local anesthesia for a time period longer than that obtainable from the substrate without the augmenting agent.
A single dose of PEG is given first, followed 1 week later by PEG + BOC 400 for 48 weeks. By second protocol amendment to P03659, participants will be rolled over into Arm 8 for the remainder of the treatment period.
The invention relates to transgenic non-human animals capable of producing heterologous antibodies, i.e.: antibodies encoded by immunoglobulin heavy and light chain genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, transgenes encoding unrearranged heterologous human immunoglobulin heat and light chains are introduced into a non-human animal thereby forming a transgenic animal capable of producing antibodies encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized; e.g., by fusing with an immortalizing cell line such as a myeloma or by manipulating such B-cells by other techniques to perpetuate a cell line capable of producing a monoclonal heterologous antibody. The invention also relates to heavy and light chain immunoglobulin transgenes for making such transgenic non-human animals as well as methods and vectors for disrupting endogenous immunoglobulin loci in the transgenic animal. The invention also includes methods to generate a synthetic immunoglobulin variable region gene segment repertoire used in transgene construction and methods to induce heterologous antibody production using animals containing heterologous rearranged or unrearranged heavy and light chain immunoglobulin transgenes.
Dietary. Two eggs will be consumed 30 minutes prior to bedtime. Energy content of dinner will be reduced to account for the calories in the bedtime snack.
It will be administered for a period of 30 days, once a day before bed, with a 15-day wash-out interval. The placebo, a drug without active substance, that will be administered to research participants will be the biotherapeutic vehicle, that is, 30% alcohol (v/v), which is commonly used as a vehicle for homeopathic medicines.
The function of traditional garlic on prevention and treatment of tumors is definite. However, the traditional garlic has strong flavor and does not accord with dietary habits; in addition, garlicin in the garlic is easy to decompose after being heated, thus the garlic is difficult to control and is not suitable for popularization. The invention provides a preparation method of an effective traditional Chinese medicine for treating the tumors and leaching liquor thereof. By digging the traditional Chinese medicine of black garlic for effectively inhibiting the tumors, the advantages of the traditional Chinese medicine of the state for treating the tumors are fully exerted to benefit tumor patients. Therefore, the research on a molecular mechanism of the black garlic is deepened; and by applying various technical means, a clinical action mechanism of the black garlic is learned from the view of cells and gene protein. For conducting and serving the clinical application, main technical strategies contained in the invention comprise black garlic leaching liquor cytotoxicity, the change of the cellular morphology caused by the treatment of the black garlic leaching liquor, the growth relation of the black garlic leaching liquor on tumor tissues in a tumor-bearing mice body, inhibiting ability of the black garlic leaching liquor on various tumor cells in the mice body, the reduction of imunodefficiency caused by cyclophosphamide through the black garlic leaching liquor and the like.
The role of tertiary lymphoid structures (TLS) in oncology is gaining interest, particularly in colorectal carcinoma, yet a thorough analysis remains elusive. This study pioneered a novel TLS quantification system for prognostic and therapeutic response prediction in colorectal carcinoma, alongside a comprehensive depiction of the TLS landscape. Utilizing single-cell sequencing, we established a TLS score within the Tumor Immune Microenvironment (TIME). Analysis of tertiary lymphoid structure-related genes (TLSRGs) in 1,184 patients with colon adenocarcinoma/rectum adenocarcinoma (COADREAD) from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases led to the identification of two distinct molecular subtypes. Differentially expressed genes (DEGs) further segregated these patients into gene subtypes. A TLS score was formulated using gene set variation analysis (GSVA) and its efficacy in predicting immunotherapy outcomes was validated in two independent cohorts. High-scoring patients exhibited a 'hot' immune phenotype, correlating with enhanced immunotherapy efficacy. Key genes in our model, including C5AR1, APOE, CYR1P1, and SPP1, were implicated in COADREAD cell proliferation, invasion, and PD-L1 expression. These insights offer a novel approach to colorectal carcinoma treatment, emphasizing TLS targeting as a potential anti-tumor strategy.
Participants will take part in a discussion program. Participants will be asked to complete 4 discussion sessions with a trained counselor over a course of a 4 week period. Participants should attend each session together as a family.
Parents of \~ 40 children and adolescents within the age group of 10-18 years suffering from anorexia or bulimia nervosa will be involved in the workshop support group for parents for a period of three months, including a written manual, a DVD (Digital Video Disc) with additional information and weekly workshops. Over the course of three months, parents will participate at the 8 workshop sessions and get the manual to read and the DVDs to use at home to illustrate workshop contents with examples and video clips.
This is a phase 3 randomized clinical trial to determine the efficacy of maintenance chemotherapy for the treatment of metastatic chemotherapy and how it should be delivered. Participants will be randomized to 3 arms. Arm 1 (control group), participants will receive only conventional chemotherapy; arm 2 (experimental group), participants will receive up to 6 cycles of maintenance chemotherapy after conventional chemotherapy; arm 3 (experimental group), after conventional chemotherapy, participants will receive maintenance chemotherapy until disease progression or intolerable toxicities. Participants in all 3 arms will receive similar conventional chemotherapy. Four to eight cycles of conventional chemotherapy with platinum-based regimen is preferred. Maintenance chemotherapy should use one of the regimens: S1 (40mg, twice a day for 14 days, every 3 weeks), capecitabine (1000mg/m\^2, twice a day for 14 days, every 3 weeks) or Tegafur-uracil (100mg/m\^2, q8h, for 14 days, every 3 weeks). The response of treatment will be evaluated according to RECIST criteria. Adverse events will be documented according to CTCAE v4.03.
It is generally recognized that tumor cells proliferate more rapidly than normal cells. Due to such an abnormally rapid proliferation rate, cancer cells constantly encounter the limits of insufficient oxygen and nutrient supplies. To satisfy their growth needs and resist adverse environmental events, tumor cells modify the metabolic pathways to produce both extra energies and substances required for rapid growth. Realizing the metabolic characters special for tumor cells will be helpful for eliminating them during therapy. Cell death is a hot topic of long-term study and targeting cell death is one of the most effective ways to repress tumor growth. Many studies have successfully demonstrated that metabolism is inextricably linked to cell death of cancer cells. Here we summarize the recently identified metabolic characters that specifically impact on different types of cell deaths and discuss their roles in tumorigenesis.
Healthy obese participants will perform the following inhalation protocol:aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula (HFNC) with 30L/min flow will be used to deliver aerosol. Volunteer seated; Preliminary acclimatization (1-2 min). Inspiratory branch: source of oxygen; HFNC; Expiratory branch: filter (Vital signs, USA). Nebulization will run until the full dose has been used (3-4 min).
PURPOSE:To remove a surplus oily matter and an incomplete liposome by providing the refining part of a liposome suspension, the feeding mechanism for feeding the liposome suspension to the refining part and the controlling mechanism for controlling the temp. of a reactor to the optimum temp. to the titled apparatus. CONSTITUTION:The apparatus body has a cylindrical shape and is connected with major equipments of 1-5 after sterilizing them. In the major equipments 1-5, 4 is the reactor, 2, 3 are hollow chambers (the refining parts) provided an ultrafiltration and an auxiliary filter and 5 is a pressure type syringe (the feeding mechanism). And the liposome suspension is produced by accommodating the liposome preparation in the reactor 4 the temp. of which is controlled, followed by agitating while bubbling it with inert gas. And the obtd. liposome suspension is refined by passing it to the refining parts 2, 3 composed of the ultrafiltration and the auxiliary filter.
FIELD: catalytic dehydrogenation of dehydrogenating hydrocarbons in reaction system comprising steel component. SUBSTANCE: it is proposed to create protective layer on steel component of reaction system. Said protective layer is resistant to attrition and carbirization and is bonded with steel component through intermediate binding layer rich in carbide. To this end, steel component is covered with galvanic, thermomechanical and paint coating from metal selected from group consisting of antimony, arsenic, bismuth, copper, chromium, gallium, germanium, indium, lead, selenium, tellurium, tin or mixtures thereof to thickness which effectively isolates steel component from hydrocarbons so as to avoid any substantial liquid embrittlement of metal. After applying said metal, thermal treatment is carried out and dehydrogenating hydrocarbon is made to contact with dehydrogenation catalyst under dehydrogenation conditions. EFFECT: more efficient dehydrogenation method. 51 cl, 1 dwg, 12 ex